CXCL9 and neoplasm: In melanoma and breast cancer cells, hypoxia induces HIF-dependent expression of BIRC2, which inhibits expression of CXCL9, thereby blocking recruitment of NK and CD8+ T cells to the tumor, leading to increased tumor growth and resistance to anti–PD-1 therapy (154).